Navigation Links
Royalty Pharma Acceptances Announcement
Date:6/6/2013

NEW YORK, June 7, 2013 /PRNewswire/ -- In accordance with Rule 17.1 and Rule 2.9 of the Irish Takeover Rules and Rule 14e-1 of the US Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today announced acceptance levels of its Increased Offer for Elan Corporation (NYSE: ELN).

Background

On 2 May 2013, Echo Pharma Acquisition Limited ("Royalty Pharma") made an offer for the entire of the issued and to be issued share capital of Elan Corporation, plc ("Elan") (the "Original Offer").

On 20 May 2013, Royalty Pharma announced the terms of a revision to the Original Offer (the "Increased Offer"). The Increased Offer was made on 23 May 2013 and is an all cash offer of US$12.50 per Elan Share (including each Elan Share represented by an Elan ADS). The full terms of, and conditions to, the Increased Offer and the procedure for acceptance are set out in the revised offer document despatched by Royalty Pharma on 23 May 2013 (the "Revised Offer Document"). The initial closing date for the Increased Offer, as set out in the Revised Offer Document, was 1:00 p.m. (Irish time) / 8:00 a.m. (New York City time) on 6 June 2013 (unless extended).

On 6 June 2013, Royalty Pharma announced that the closing date for the Increased Offer was extended until 1:00 p.m. (Irish time) / 8:00 a.m. (New York City time) on Friday, 21 June 2013 and will remain open for acceptance until that time (unless further extended).

A reference in this announcement to the "Offer" means the Original Offer (including where the context so requires, any subsequent revision, variation, extension or renewal of the Original Offer, including in connection with the Increased Offer). Capitalised terms used but not defined in this announcement shall have the meaning given to them in the Revised Offer Document.

Royalty Pharma is making this announcement in accordance with Rule 1
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Royalty Pharma Responds To Elans Tysabri Valuation
2. Royalty Pharma Response To Elans "Categorical View On Value"
3. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
4. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
5. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
6. Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
7. Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
8. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
9. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
10. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
11. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015  TissueGene, Inc. a clinical-stage biopharmaceutical ... the field of cell therapy, today announced the ... of Chief Operating Officer.  Mr. Newman was most ... Clinical Operations at ZIOPHARM Oncology, a ... gene expression, control and cell technologies in the ...
(Date:4/21/2015)... and PARIS and BURLINGTON, N.C. , ... (NYSE: DGX ), the world,s leading provider ... National Institute of Health and Medical Research institution, ... they co-founded to provide scientists and laboratory organizations ... and BRCA2 genetic data. The program,s goal is ...
(Date:4/21/2015)... April 21, 2015 /PRNewswire/ -- Mindray Medical International Limited ("Mindray", ... marketer of medical devices worldwide, today announced that it ... ended Mar 31, 2015 after the U.S. market closes ... earnings conference call at 8:00 AM on May 12, ... 2015 Beijing/Hong Kong Time). Dial-in details ...
Breaking Medicine Technology:TissueGene, Inc. Hires Robert Newman as Chief Operating Officer 2Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 2Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 3Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 4Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 5Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 6Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers 7Mindray to Report 2015 First Quarter Financial Results on May 11, 2015 2
... May 9 Osteoarthritis is a,painful and ... people in the United States. It is ... The novel investigational pain medication,tapentadol, a centrally ... with joint-disease pain, compared to those treated ...
... Biosciences, Inc.,(Nasdaq: RDEA ), a company focused ... for the treatment of HIV, cancer and,inflammatory diseases, ... been appointed Senior Vice President, Finance and Operations ... will resign from our board of,directors shortly thereafter. ...
Cached Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6
(Date:4/21/2015)... York, NY (PRWEB) April 21, 2015 What ... Jessica Parker, Tom Ford and Ted Turner have in common? ... of the 50 Most Powerful Americans 50+. In a 16-page ... Chief of more than 50 magazines and 25 websites, along ... on the power they wield through the unique lens of ...
(Date:4/21/2015)... 21, 2015 Zane Benefits, a software ... its CEO Rick Lindquist has been selected as one ... According to Rick Lindquist, “There is a massive shift ... Benefits’ small business solutions are at its forefront. Our ... Employee Benefit Adviser’s Rising Stars.” , According to the ...
(Date:4/21/2015)... Let's face it; a lot of skin ... and complex routines for hundreds of dollars. Block ... gimmicks, as the sun is the leading cause of skin ... more than just daily sun protection; it is also about ... new Purifying Facial Cleanser and Revitalizing Night ...
(Date:4/21/2015)... April 21, 2015 Quark Software ... a new knowledge management solution that enables large ... of policies and procedures. With Quark Procedure Management, ... content that is easy to save, search and ... to risk and compliance issues. Examples of policies ...
(Date:4/21/2015)... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology ... report results for the first quarter of 2015 on ... market. , The Company will host a conference ... release at 4:30 PM ET. Investors interested in ... at 1.877.407.0993 or use the direct dial-in number 1.201.689.8795. ...
Breaking Medicine News(10 mins):Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 2Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 3Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 4Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Block Island Organics Debunks Skin Care Myths with New Products 2Health News:Block Island Organics Debunks Skin Care Myths with New Products 3Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 2Health News:Quark Software Inc. Introduces Procedure Management Solution for Global 2000 3Health News:AxoGen, Inc. to Report First Quarter Financial Results on May 5, 2015 2
... Fla. October 24, 2011 Patients in the United ... able to benefit from a new treatment that is already ... The treatment, called collagen crosslinking, improved vision in almost 70 ... clinical trial in Milan, Italy. The treatment is in clinical ...
... Heavy alcohol consumption may be linked to a ... and increased consumption of black tea and fruit are ... three separate studies presented at CHEST 2011, the 77th ... (ACCP), heavy alcohol consumption was related to increased risk ...
... Lung Cancer Mortality Rates , (#1111771, Tuesday, October ... has one of the highest mortality rates in the ... on data from the National Cancer Institute Surveillance, Epidemiology, ... Regional Medical Center in Flint, Michigan and the Mayo ...
... training on a take-home simulator do a better job once ... told the Canadian Cardiovascular Congress 2011, co-hosted by the Heart ... Dr. Lam and a multidisciplinary surgical team developed a kit ... be taken home by trainees to practice a highly technical ...
... reconstruction with tissue from their own abdomen experience significant ... as three weeks after surgery. That is one of ... in Cancer , a peer-reviewed journal of the ... to breast cancer survivors who are contemplating these types ...
... -- While there are challenges, Halloween can still be fun ... enjoy Halloween and enjoy some of the sweets the holiday ... and senior scientist at the University of Alabama at Birmingham ... "We give parents and kids three options and let them ...
Cached Medicine News:Health News:Vitamin B-based treatment for corneal disease may offer some patients a permanent solution 2Health News:Heavy alcohol consumption linked to lung cancer 2Health News:CHEST 2011: Embargoed studies highlight new lung cancer and COPD research 2Health News:CHEST 2011: Embargoed studies highlight new lung cancer and COPD research 3Health News:Heart surgeons-in-training benefit from hands-on homework 2Health News:Advanced post-mastectomy breast reconstruction improves women's psychosocial and sexual well-being 2Health News:Healthy Halloween Advice for Children With Diabetes 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: